Cargando…
Identification of a Novel P190-Derived Breakpoint Peptide Suitable for Peptide Vaccine Therapeutic Approach in Ph+ Acute Lymphoblastic Leukemia Patients
Ph+ acute lymphoblastic leukemia (Ph+ ALL) is a high-risk acute leukemia with poor prognosis, in which the specific t(9;22)(q34;q11) translocation results in a chimeric bcr-abl (e1a2 breakpoint) and in a 190 KD protein (p190) with constitutive tyrosine kinase activity. The advent of first- and secon...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3505930/ https://www.ncbi.nlm.nih.gov/pubmed/23198152 http://dx.doi.org/10.1155/2012/150651 |
_version_ | 1782250829183451136 |
---|---|
author | Ippoliti, Micaela Defina, Marzia Gozzini, Antonella Baratè, Claudia Aprile, Lara Pietrini, Alice Gozzetti, Alessandro Raspadori, Donatella Lauria, Francesco Bocchia, Monica |
author_facet | Ippoliti, Micaela Defina, Marzia Gozzini, Antonella Baratè, Claudia Aprile, Lara Pietrini, Alice Gozzetti, Alessandro Raspadori, Donatella Lauria, Francesco Bocchia, Monica |
author_sort | Ippoliti, Micaela |
collection | PubMed |
description | Ph+ acute lymphoblastic leukemia (Ph+ ALL) is a high-risk acute leukemia with poor prognosis, in which the specific t(9;22)(q34;q11) translocation results in a chimeric bcr-abl (e1a2 breakpoint) and in a 190 KD protein (p190) with constitutive tyrosine kinase activity. The advent of first- and second-generation tyrosine kinase inhibitors (TKIs) improved the short-term outcome of Ph+ ALL patients not eligible for allo-SCT; yet disease recurrence is almost inevitable. Peptides derived from p190-breakpoint area are leukemia-specific antigens that may mediate an antitumor response toward p190+ leukemia cells. We identified one peptide named p190-13 able to induce in vitro peptide-specific CD4+ T cell proliferation in Ph+ ALL patients in complete remission during TKIs. Thus this peptide appears a good candidate for developing an immune target vaccine strategy possibly synergizing with TKIs for remission maintenance. |
format | Online Article Text |
id | pubmed-3505930 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | Hindawi Publishing Corporation |
record_format | MEDLINE/PubMed |
spelling | pubmed-35059302012-11-29 Identification of a Novel P190-Derived Breakpoint Peptide Suitable for Peptide Vaccine Therapeutic Approach in Ph+ Acute Lymphoblastic Leukemia Patients Ippoliti, Micaela Defina, Marzia Gozzini, Antonella Baratè, Claudia Aprile, Lara Pietrini, Alice Gozzetti, Alessandro Raspadori, Donatella Lauria, Francesco Bocchia, Monica Leuk Res Treatment Research Article Ph+ acute lymphoblastic leukemia (Ph+ ALL) is a high-risk acute leukemia with poor prognosis, in which the specific t(9;22)(q34;q11) translocation results in a chimeric bcr-abl (e1a2 breakpoint) and in a 190 KD protein (p190) with constitutive tyrosine kinase activity. The advent of first- and second-generation tyrosine kinase inhibitors (TKIs) improved the short-term outcome of Ph+ ALL patients not eligible for allo-SCT; yet disease recurrence is almost inevitable. Peptides derived from p190-breakpoint area are leukemia-specific antigens that may mediate an antitumor response toward p190+ leukemia cells. We identified one peptide named p190-13 able to induce in vitro peptide-specific CD4+ T cell proliferation in Ph+ ALL patients in complete remission during TKIs. Thus this peptide appears a good candidate for developing an immune target vaccine strategy possibly synergizing with TKIs for remission maintenance. Hindawi Publishing Corporation 2012 2012-02-15 /pmc/articles/PMC3505930/ /pubmed/23198152 http://dx.doi.org/10.1155/2012/150651 Text en Copyright © 2012 Micaela Ippoliti et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Ippoliti, Micaela Defina, Marzia Gozzini, Antonella Baratè, Claudia Aprile, Lara Pietrini, Alice Gozzetti, Alessandro Raspadori, Donatella Lauria, Francesco Bocchia, Monica Identification of a Novel P190-Derived Breakpoint Peptide Suitable for Peptide Vaccine Therapeutic Approach in Ph+ Acute Lymphoblastic Leukemia Patients |
title | Identification of a Novel P190-Derived Breakpoint Peptide Suitable for Peptide Vaccine Therapeutic Approach in Ph+ Acute Lymphoblastic Leukemia Patients |
title_full | Identification of a Novel P190-Derived Breakpoint Peptide Suitable for Peptide Vaccine Therapeutic Approach in Ph+ Acute Lymphoblastic Leukemia Patients |
title_fullStr | Identification of a Novel P190-Derived Breakpoint Peptide Suitable for Peptide Vaccine Therapeutic Approach in Ph+ Acute Lymphoblastic Leukemia Patients |
title_full_unstemmed | Identification of a Novel P190-Derived Breakpoint Peptide Suitable for Peptide Vaccine Therapeutic Approach in Ph+ Acute Lymphoblastic Leukemia Patients |
title_short | Identification of a Novel P190-Derived Breakpoint Peptide Suitable for Peptide Vaccine Therapeutic Approach in Ph+ Acute Lymphoblastic Leukemia Patients |
title_sort | identification of a novel p190-derived breakpoint peptide suitable for peptide vaccine therapeutic approach in ph+ acute lymphoblastic leukemia patients |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3505930/ https://www.ncbi.nlm.nih.gov/pubmed/23198152 http://dx.doi.org/10.1155/2012/150651 |
work_keys_str_mv | AT ippolitimicaela identificationofanovelp190derivedbreakpointpeptidesuitableforpeptidevaccinetherapeuticapproachinphacutelymphoblasticleukemiapatients AT definamarzia identificationofanovelp190derivedbreakpointpeptidesuitableforpeptidevaccinetherapeuticapproachinphacutelymphoblasticleukemiapatients AT gozziniantonella identificationofanovelp190derivedbreakpointpeptidesuitableforpeptidevaccinetherapeuticapproachinphacutelymphoblasticleukemiapatients AT barateclaudia identificationofanovelp190derivedbreakpointpeptidesuitableforpeptidevaccinetherapeuticapproachinphacutelymphoblasticleukemiapatients AT aprilelara identificationofanovelp190derivedbreakpointpeptidesuitableforpeptidevaccinetherapeuticapproachinphacutelymphoblasticleukemiapatients AT pietrinialice identificationofanovelp190derivedbreakpointpeptidesuitableforpeptidevaccinetherapeuticapproachinphacutelymphoblasticleukemiapatients AT gozzettialessandro identificationofanovelp190derivedbreakpointpeptidesuitableforpeptidevaccinetherapeuticapproachinphacutelymphoblasticleukemiapatients AT raspadoridonatella identificationofanovelp190derivedbreakpointpeptidesuitableforpeptidevaccinetherapeuticapproachinphacutelymphoblasticleukemiapatients AT lauriafrancesco identificationofanovelp190derivedbreakpointpeptidesuitableforpeptidevaccinetherapeuticapproachinphacutelymphoblasticleukemiapatients AT bocchiamonica identificationofanovelp190derivedbreakpointpeptidesuitableforpeptidevaccinetherapeuticapproachinphacutelymphoblasticleukemiapatients |